Additionally, a broader analysis incorporating 16 studies, comprising five trials, 10 controlled cohorts, and one real-world study, evaluated ICI-treated NSCLC patients with EGFR mutations after TKI failure. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.